Health & Wellness

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled

The clinical trial is being led locally by Eric D. Whitman, MD, FACS. Credits: Atlantic Health System

MORRISTWON, NJ - Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multi-center Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Overlook Medical Center and Morristown Medical Center.

Sign Up for E-News

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multi-center, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News


Upcoming Events


Tue, March 20, 1:30 PM

Summit Free Public Library, Summit

Age 3-K: Programs with Mrs. Wheeless

Arts & Entertainment Education


Wed, March 21, 7:00 PM

Summit Free Public Library, Summit

Networking and Interviewing 'IQ' Workshop

Arts & Entertainment Business & Finance Education Other

Thu, March 22, 12:00 PM

SAGE Eldercare, Summit

FREE Tax Assistance

Community Calendar

Summit Fire Department Blotter

01/01/2018 9:26 am     FD dispatched to a motor vehicle accident, car vs. pole in front of 196 GLENSIDE AVENUE.  On arrival occupant was out of the vehicle.  Summit EMS assumed patient contact. FD made notification to the power company to make repairs.  Summit PD remained on scene for traffic control and road closure until repairs were made.

01/02/2018 7:36 pm ...

Summit Police Blotter

March 12, 2018

3/3 - Daniel T. Lipkin, 20, of Millington was arrested and charged with possession of marijuana, possession of paraphernalia and possession of an alcoholic beverage under legal age. Mr. Lipkin was processed and released with a pending court date.

3/3 - Taurino Alday-Benitez, 28, of Summit was arrested and charged with driving while intoxicated. Mr. Alday-Benitez was processed and released with ...

Video: Point View's Dietze Talks Bond Surrogate Bargains

March 20, 2018

Point View Wealth Management's Founder, President and Chief Investment Strategist, David Dietze, live on BNN / Bloomberg on finding investment opportunities among bond surrogates:

For nearly 25 years, Point View Wealth Management, Inc. has been working with families in Summit and beyond, providing customized portfolio management ...

Summit Area YMCA's Next LIVESTRONG Program Session Begins Mar. 20

A new spring session for The LIVESTRONG at the YMCA program, a 12-week cancer recovery program, will begin at the Berkeley Heights YMCA on March 20. The program is a research-based physical and wellness program in which certified Summit Area YMCA trainers work with participants to achieve their goals. LIVESTRONG  at the YMCA helps cancer survivors who find themselves in the ...

Profit from Recent Volatility with Stock Market Bargains

Markets retreated in February, the worst down month in two years. A record surge in volatility caused several ETFs designed as leveraged bets on low volatility to plunge, with at least one being forced to liquidate and hand its investors a near total loss.

The Causes of February’s Market Retreat

The initial catalyst for the sell off was inflation. The January jobs report showed ...


AtlantiCast: Episode 13

On this episode of AtlantiCast, new clinical studies in the fields of cardiology and immunotherapy, national and statewide recognitions for Atlantic Health System medical centers and the inaugural AtlantiCast Collab Challenge!


Coffee, Tea or Fleas?

Two ducks are on a flight to Miami.  The first duck says to the second, “you flying south for the winter?”  The second duck replies, “Oh wow, a talking emotional support duck!”


Pa rum pum.


There have been a lot of news stories lately about animals traveling on airplanes.  Some are humorous, like the woman who recently tried to bring ...

Learn a Language @ Your Library

Anyone can learn a language at the Summit Free Public Library!

Did you know that the Summit Library has a subscription to Muzzy Club? Funded by a grant from the Union County Board of Chosen Freeholders, Muzzy Club is an online resource that allows Summit Library cardholders of all ages to learn a new language. Languages in Muzzy Club include British and American English, Spanish, ...